| Insight |
sivir:
tial
ent for
9
g, currently in
ows promising
19
baseline on a predefined seven-point
scale, ranging from hospital discharge to
increasing levels of oxygen support to death.
Patients achieved clinical recovery if they no
longer required oxygen support and medical
care or were discharged from the hospital.
Exploratory Analysis
In an exploratory analysis, patients in the
study who received Remdesivir within
10 days of symptom onset had improved
outcomes compared with those treated
after more than 10 days of symptoms.
Pooling data across treatment arms, by Day
14, 62 per cent of patients treated early were
able to be discharged from the hospital,
compared with 49 percent of patients who
were treated late.
“These data are encouraging. They
indicate patients who received a shorter,
five-day course of Remdesivir experienced
similar clinical improvement as patients
who received a 10-day treatment
course,” said Aruna Subramanian, MD,
Clinical Professor of Medicine, Chief,
Immunocompromised Host Infectious
Diseases, Stanford University School of
Medicine and one of the lead investigators
of the study.
“While additional data is still needed,
these results help to bring a clearer
understanding of how treatment with